Leveraging MIDD to Shape Development Strategy & Evidence Generation

• Moving beyond the use of MIDD solely for regulatory submissions to support critical development and lifecycle management decisions
• Using quantitative evidence to inform dosing, special populations, benefit-risk assessments, and broader clinical development strategies
• Case studies demonstrating how MIDD has influenced regulatory discussions, development plans, and cross-functional decision-making

Speakers: